The Federal Circuit won’t block the launch of MSN Pharmaceuticals Inc.'s copy of the lucrative heart-failure drug Entresto while Novartis Pharmaceuticals Corp. appeals its loss in a patent ...

Novartis reported an impressive 11% increase in sales in constant currency, accompanied by a 21% rise in core operating income for Q2 2025. This growth underscores the company’s strong financial ...

27 May 2025 Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.